Does Suboxone work for kratom addiction?

At a glance: the evidence summary

Key Takeaways

• Published case series show buprenorphine works for kratom use disorder. The largest reported 71% retention at follow-up and 82% kratom abstinence at 8 to 12 weeks.
• The evidence is real but early. It rests on case series and clinical experience, not randomized trials. Researchers call for larger studies, and the field is still maturing.
• The biology matches. Kratom dependence runs through opioid receptors, which is precisely what buprenorphine is built to stabilize. This is not a repurposed medication for an unrelated problem.
• Stabilizing dose is not predictable from kratom use amount. This is why buprenorphine dose is titrated to symptoms, not calculated from prior use.
• One expert group has cautioned against using buprenorphine first-line for milder kratom dependence, particularly in people with no prior opioid exposure, because it can introduce opioid tolerance. This is a case-by-case clinical judgment.

Why buprenorphine works for kratom: the short version

Kratom's primary alkaloids, mitragynine and 7-hydroxymitragynine, activate mu-opioid receptors. Repeated activation of those receptors produces the neuroadaptation underlying physical dependence. Buprenorphine is a high-affinity partial agonist at the same receptor. It occupies and stabilizes mu-opioid receptors, which is why it prevents withdrawal and reduces cravings regardless of which opioid-acting substance drove the dependence.

This is not a case of using an OUD medication and hoping it generalizes. The mechanism is a direct pharmacological match. For the full receptor-level explanation, see Is Kratom an Opioid? and the mechanism deep-dive.

What the research actually shows

The Broyan et al. case series (Substance Abuse, 2022)

The largest published case series comes from Broyan, Brar, Allgaier, and Allgaier, published in Substance Abuse in 2022. It is the most detailed clinical data set on buprenorphine for kratom use disorder to date.

The patients: 28 adults who identified kratom as their primary substance of use. Duration of use ranged from 1 month to 25 years. All were treated with buprenorphine/naloxone in an outpatient office-based setting.

Retention: As of the follow-up date, 20 of 28 patients (71%) were still receiving outpatient buprenorphine treatment. Six were lost to follow-up due to missed appointments. One tapered down and self-discharged. One relocated. Those who remained had been in treatment for 5 to 22 months, with an average duration of 11 months.

Kratom abstinence: Because standard urine drug tests do not detect mitragynine, the study used liquid chromatography-mass spectrometry (LC-MS/MS), which can quantitatively detect it. Results:

Dose finding: There was no statistically significant correlation between the stabilizing buprenorphine dose and how much kratom the patient had been using prior to treatment. This finding is consistent with what is known about OUD treatment generally: dose is titrated to symptoms, not calculated from prior substance amount.

Supporting case reports and series

Several additional published cases support the same direction:

• Arhin et al. (Cureus, 2023): Successful management of kratom use disorder with buprenorphine and naloxone; patient abstinent from kratom within one week of initiation.
• Schmuhl et al. (Substance Abuse, 2020): Home induction and outpatient treatment of kratom use disorder with buprenorphine/naloxone in a young adult, with complete remission after a supervised six-month taper.
• Gittins and Cole (Drug Science, Policy and Law, 2021): Case report of buprenorphine management of kratom dependency.

A 2026 AIM Clinical Cases paper by Barrett, Hendy, Lira, and colleagues reviewed the evidence and stated that buprenorphine "is recommended as the preferred treatment of opioid dependence" for kratom and 7-OH cases, citing its known safety profile, established efficacy for OUD, and regulated manufacturing as the basis.

A systematic review

A systematic review of pharmacotherapy for kratom use disorder found buprenorphine to be the most consistently used and effective approach in published cases. The review acknowledged the evidence is emerging and called for prospective studies.

The honest limits of the evidence

This section exists because it is where trust is built.

Evidence tier: The support for buprenorphine in kratom use disorder consists of case series, case reports, and extrapolation from OUD research principles. No randomized controlled trial has been conducted specifically for kratom use disorder treatment. Researchers themselves call for such studies, and the field is still developing them.

The published critique: A Letter to the Editor responding to the Broyan et al. case series (Smith and Weiss, Substance Abuse, 2022) flagged inconsistencies and missing context in the report, including a dose extrapolation from animal models that the authors applied to humans. The letter noted these are not problems unique to the Broyan paper but present across kratom-specific case reports. The Broyan findings are promising, not definitive.

Off-label status: Buprenorphine is FDA-approved for opioid use disorder, not specifically for kratom use disorder. Its use for kratom is clinically supported but off-label. This is common in medicine when the pharmacological rationale is strong and the clinical experience is positive, but it is a distinction worth knowing.

The counterpoint for milder cases: A clinical guidance group has cautioned against using buprenorphine as a first-line approach for people with mild kratom dependence, particularly those with no prior opioid exposure, because initiating buprenorphine introduces opioid receptor occupancy in someone who did not previously have it. For people with milder leaf-based dependence and no prior failed attempts, a supervised taper or monitored cold-turkey approach may be more appropriate than immediate buprenorphine. This is a case-by-case clinical judgment made during evaluation.

For a comparison of all three approaches, see Quitting Kratom Cold Turkey vs. Tapering vs. Suboxone.

What "working" actually looks like in practice

Early stabilization: Most patients in the published cases experienced significant improvement in withdrawal and cravings within the first days of a correctly timed induction. The first few weeks involve dose adjustment as kratom clears and buprenorphine levels stabilize.

Abstinence from kratom: The 82% negative kratom urine test rate at 8 to 12 weeks in the Broyan series reflects a real clinical signal. Most patients who stay engaged with treatment stop using kratom within the first two to three months.

Treatment is not only medication: The programs in the published case series paired buprenorphine with counseling, psychoeducation, and relapse-prevention support. Duration is individualized: some patients remain on maintenance for months or years, others pursue a supervised taper after stabilization. Both are appropriate outcomes.

Staying in treatment is itself the intervention: The 11-month average retention in the Broyan series reflects the fact that staying engaged with care is a large part of what produces good outcomes. Buprenorphine supports that engagement by removing the withdrawal and craving cycle that makes staying in recovery harder.

Frequently Asked Questions

Does Suboxone help with kratom withdrawal?

Yes. Buprenorphine prevents most or all of the acute withdrawal phase when started at the right time during the withdrawal window. In the case series literature, patients who were correctly inducted reported rapid and significant relief from withdrawal symptoms within the first dose. The timing requirement (waiting until mild-to-moderate withdrawal before the first dose) is what makes this effective and prevents precipitated withdrawal.

What is the success rate of Suboxone for kratom?

In the largest published case series (Broyan et al., 2022, 28 patients), 71% remained in outpatient treatment at follow-up, with an average retention of 11 months. Among those in treatment, 82% tested negative for mitragynine at 8 and 12 weeks. These are promising figures from an outpatient real-world setting, though the study's limitations (single center, small sample, case series design) mean they are not definitive.

How long do you stay on Suboxone for kratom?

There is no fixed endpoint. Duration is individualized, based on clinical response, patient goals, and life circumstances. The Broyan et al. case series showed a range of 5 to 22 months. Some patients taper off after stabilization; others remain on maintenance. Longer treatment is associated with better outcomes in OUD research generally. Your prescriber will guide the plan based on how you are doing.

Is buprenorphine the right choice for my level of kratom use?

That depends on your specific situation. Buprenorphine is the recommended first-line approach for significant kratom or 7-OH dependence, daily use, prior failed attempts, or concentrated 7-OH use. For mild, short-term leaf use with no prior failed attempts, a supervised taper may be a more appropriate starting point. The evaluation is where this is determined. See how to access that evaluation online.

Will I have to take Suboxone forever?

No. Many people treated for kratom use disorder with buprenorphine taper off the medication after achieving stability. The published cases include both people on long-term maintenance and people who completed supervised tapers and remained abstinent. The goal is stability and quality of life, and the specific path to that end is individualized.